News
Moderna’s New Flu Shot Shows Strong Results in Older Adults
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA. Copyright © 2025 HealthDay. All rights reserved.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...
Investor's Business Daily on MSN1d
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback